Document is current
Any future updates will be listed below
-
Authors
Nazaret, Achille
Fan, Joy Linyue
Lavallée, Vincent-Philippe
Burdziak, Cassandra
Cornish, Andrew E.
Kiseliovas, Vaidotas
Bowman, Robert L.
Masilionis, Ignas
Chun, Jaeyoung
Eisman, Shira E.
Wang, James
Hong, Justin
Shi, Lingting
Levine, Ross L.
Mazutis, Linas
Blei, David
Pe’er, Dana
Azizi, Elham
-
Funding
Funding for this research was provided by:
Eric and Wendy Schmidt Center
Africk Family Fund
Columbia University Van C. Mow fellowship
Columbia Avanessians fellowship
Vanier Canada Graduate Scholarship
Clinical Research Scholarship from the FRQS
Chan Zuckerberg Initiative (2022-253560, 2022-253560)
NCI (R35CA197594, U54 CA209975)
MSKCC Support Grant (P30CA008748)
Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Howard Hughes Medical Institute
National Cancer Institute,United States (R00CA230195)
Columbia University Data Science Institute
Irving Institute for Cancer Dynamics Seed Funding
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 2 July 2025
First Online: 23 July 2025
Declarations
:
: The genomic sequencing study used in our acute myeloid leukemia analysis was approved by the Institutional Review Board/Privacy Board-B of Memorial Sloan-Kettering Cancer Center (Protocol #17-549) on November 4, 2017.
: Not applicable.
: D.P. is on the scientific advisory board of Insitro. R.L.L. is on the supervisory board of Qiagen and on the board of directors of Ajax Therapeutics, for which he receives compensation and equity support. He is or has recently been a scientific advisor to Imago, Mission Bio, and Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics, and Isoplexis, for which he receives equity support. He also has research support from Ajax and AbbVie, consulted for Janssen, and received honoraria from Astra Zeneca and Kura for invited lectures.
